"This set of proposals is squarely aimed at addressing practices by drug middlemen that are driving up health costs for patients and taxpayers. I look forward to a constructive, bipartisan markup as the committee considers additional proposals from members. This week marks another important step towards a rational prescription drug pricing system that leads to lower costs and better outcomes for all Americans."